Lv5
1050 积分 2023-04-17 加入
Guselkumab in moderately to severely active ulcerative colitis: Another interleukin-23p19 subunit inhibitor or more?
5天前
已关闭
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing
5天前
已完结
How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?
6天前
已完结
Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis
6天前
已完结
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
6天前
已完结
P74 Improvement in inflammatory biomarkers through week-12 in guselkumab-treated patients with moderately-to-severely active ulcerative colitis: results from phase-3 QUASAR induction study
8天前
已关闭
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
9天前
已完结
Management of ulcerative colitis: where are we at and where are we heading?
9天前
已完结
Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
9天前
已完结
皖公网安备34019202002308
